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Cardiovascular diseases (CVD) and cancer are 
the two leading disease burdens worldwide. 
Epidemiological and demographic transi-
tions, improved survival and better screening 
at health system level are among the factors 
leading to increasing overlap between these 
separate conditions, both in terms of aeti-
ology and outcome. The number of cancer 
survivors will rise to 19 million in the USA by 
20241 and four million in the UK by 2040.2 
New immune, biological and small-molecule 
therapies as well as existing chemotherapies 
alike have increased the proportion of cancer 
survivors for whom morbidity and mortality 
from CVD (‘cardiotoxicity’) supersedes that 
arising from cancer. A new medical specialty 
has evolved, involving multidisciplinary 
teams from both oncology and cardiology. 
Cardio-oncology recognises that today’s cancer 
patient is tomorrow’s cardiac patient and aims to 
prevent, diagnose and treat cardiotoxicity.
‘Cardiotoxicity’ was first coined to describe 
the cardiac toxicity from local anaesthetics, 
mercurial diuretics and digitalis in 1946. In 
the 1970s, the term was also used to describe 
the cardiac complications associated with 
anthracyclines (daunorubicin and doxoru-
bicin), combination therapy (doxorubicin 
and radiotherapy) and for 5-fluorouracil. 
Early reports of ‘cardiotoxicity’ were predi-
cated on the clinical syndrome of heart failure 
(HF), and later led to the development of a 
lifetime cumulative limit for anthracycline 
dose, although adverse cardiac effects can 
arise at lower doses.
There are already targeted, immune-medi-
ated, biologically active small molecule, and 
monoclonal antibody therapies for over 200 
recognised cancers,3 and ‘precision medicine’ 
(which uses information about a person’s 
genes, proteins and environment to prevent, 
diagnose and treat disease4) promises further 
advances. Unfortunately, the same precision 
is currently lacking in the prediction, prog-
nosis and treatment of cardiotoxicity and in 
the very definition of ‘cardiotoxicity’ itself. 
Cardio-oncology is a useful lens to study the 
far-reaching implications of imprecise classifi-
cations within precision medicine for clinical 
practice and research.
The most widely recognised diagnosis of 
cardiotoxicity is based on changes in left 
ventricular (LV) systolic function measured 
by a single method, usually left ventric-
ular ejection fraction (LVEF), sometimes 
on a single occasion. A fall below a certain 
level or an absolute change in LVEF is inter-
preted as an early harbinger of cardiotox-
icity, but thresholds for clinical decisions 
vary across consensus guidelines (table 1). 
LVEF measurement is subject to consider-
able intraobserver and interobserver vari-
ability,5 as well as discrepancy across imaging 
modalities. The diagnosis of HF involves 
assessment and monitoring of LVEF, yet the 
comparison between left ventricular dysfunc-
tion in HF (which itself has problems with 
universality and generalisability of defini-
tions) and cardiotoxicity has not been made, 
whether in terms of aetiology, epidemiology 
or prevention.
Cardiac dysfunction, assessed by LVEF, 
may be the most common manifestation 
of chemotherapy using anthracyclines or 
trastuzumab. However, limiting detection 
of cardiotoxicity to a single measure of LV 
mechanical function underestimates the clin-
ical significance of other manifestations. For 
example, there is increasing evidence that, as 
well as structural change (eg, fall in LVEF), 
common anthracycline regimens trigger elec-
trical (eg, supraventricular arrhythmia or 
atrial fibrillation) and biomarker (eg, rise in 
N-terminal pro brain natriuretic peptide or 
cardiac troponin) cardiotoxicity.
Advanced cancer therapies based on preci-
sion targets within the cancer kinome (the 
complete set of protein kinases encoded in 
its genome) continue to improve outcomes. 
However, with each novel therapy, new and 
often unforeseen cardiotoxicities have been 
reported. A broad range of cardiac sequelae 
are provoked by ‘on-’ and ‘off-’ target 
effects, including coronary artery disease, 
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myocarditis, stress cardiomyopathy, hypertension, arterial 
and venous thrombosis, pulmonary hypertension and QT 
prolongation. However, these diverse cardiac manifesta-
tions may also be ambiguously labelled as ‘cardiotoxicity’ 
without adequate distinction from the aforementioned 
structural, electrical and biomarker subtypes.6 Specific 
examples include coronary artery spasm and stress cardio-
myopathy from fluoropyrimidines, sunitinib, bevacizum-
ab,or rituximab; venous thromboembolism from nilotinib 
or thalidomide; pulmonary hypertension provoked by 
dasatanib; peripheral artery disease and stroke from nilo-
tinib; hypertension from carfilzomib and sunitinib; and 
Table 1 Variation in definitions of cardiotoxicity across standards organisations
Standards organisation Definition of cardiotoxicity Comments
ASE/EACVI LVEF fall by >10% to absolute EF <53% Change in LV function may be global or regional (septum)
Symptomatic or asymptomatic for HF
ESC LVEF fall by >10% from baseline to EF <50% Symptomatic or asymptomatic for HF
NCI CTCAE
HF grade 1–5
Grade 1 (asymptomatic)
Grade 2 (mild to moderate symptoms)
Grade 3 (symptomatic on minimal exertion or at rest)
Grade 4 (life-threatening)
Grade 5 (death)
CCS LVEF fall by >10% from baseline or LVEF <53% Guidelines also recommend (1) 3D echocardiography or same 
imaging modality during cancer therapy, (2) myocardial strain 
imaging and (3) cardiac biomarkers (N-terminal pro brain natriuretic 
peptide, troponin) for early detection
ESMO Symptomatic decline in LVEF of at least 5% to 
<55% or asymptomatic decline in
LVEF of at least 10% to <55%
Symptoms for congestive HF with signs including but not limited to 
S3 gallop, tachycardia or both
Decline in LVEF either global or more severe in the septum
Adapted from CCS guidelines by Virani et al CJC 2016 (32) 831–841 and ESMO statement Curigliano et al Annals Oncol 2012 23 (suppl 7); vii 
155–vii 166. 
ASE, American Society of Echocardiography; CCS, Canadian Cardiovascular Society; CTCAE, Common Terminology Criteria for Adverse 
Events; EACVI, European Association of Cardiovascular Imaging; EF, ejection fraction; ESC, European Society of Cardiology; ESMO, 
European Society of Medical Oncology; HF, heart failure; LVEF, left ventricular ejection fraction; NCI, National Cancer Institute.
Table 2 ‘Cardiotoxicity’ of common cancer therapies
LVSD HTN Angina ACS Takotsubo Stroke PAD PHTN
DVT/
PE
Anthracyclines X
5-FU X X X X
Gemcitabine X X
Paclitaxel X X X X
Cisplatin X X X X X
Bleomycin X X X X
Vincristine X X X
Cyclophos-phamide X X X
mTOR inhibitors X X X
Carfilzomib X X X X
Bevacizumab X X X X X X X
Sunitinib X X X X X X X
Nilotinib X X X X X
Dasatanib X X
Thalidomide X
Rituximab X X X X
ACS, acute  coronary syndrome; DVT/PE, deep  vein thrombosis/pulmonary embolism; 5-FU, 5 fluorouracil; EF, ejection fraction; HF, heart 
failure; HTN, hypertension; LVSD, left ventricular systolic dysfunction >2% incidence as clinical HF or symptomatic or asymptomatic 
fall in EF >10%; mTOR, mammalian Target of Rapamycin; PAD, peripheral arterial disease; PHTN, pulmonary  hypertension; Takutsobo, 
Takutsobo cardiomyopathy (adapted from Hermann Circ 2016; 133: 1272–89 and Zamorano et al EHJ 2016;37: 2768.
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fulminant myocarditis with immune checkpoint inhib-
itors (table 2.) These multiple untoward cardiovascular 
toxicities can be explained mechanistically by receptor 
interactions within the cardiac and cancer kinome.7 
Thus, an expanding arsenal of anticancer treatments 
necessitates a more precise definition of cardiotoxicity.
Beyond diagnosis or cardiotoxicity, prognosis and risk 
prediction also present obstacles due to the variable 
course of cardiotoxicity by timing (early versus late), 
potential reversibility, target population (eg, childhood 
vs adult cancer survivors), underlying cardiovascular risk 
and the chemotherapy regimen. The benefits from preci-
sion medicine for cancer may have unpredictable costs 
in the form of ‘cardiotoxicities’ and studies with long-
term follow-up are required to better understand disease 
trajectories.
A potential solution would be a universal definition 
of cardiotoxicity. We propose a novel nomenclature for 
cardiotoxicity that classifies cardiovascular side effects 
into a structured taxonomy based on time course (acute 
or chronic, early or late), population demographic (adult 
or paediatric as appropriate), putative source substrate 
(anthracycline, proteasome and vascular endothelial 
growth factor) and affected cardiovascular phenotype 
(arrhythmogenic or cardiomyopathic cardiotoxicity). 
Based on this structured taxonomy, one could reli-
ably describe and distinguish cardiotoxicity in adults 
or children due to anthracyclines, trastuzumab, dasa-
tanib, carfilzomib or immunotherapy, respectively. For 
example, anthracycline cardiomyopathy in early adult-
hood and late childhood could be differentiated, as well 
as late HER2/neu cardiac dysfunction, pulmonary hyper-
tension associated with dasatanib, carfilzomib-associated 
hypertension and programmed cell death-1 (PD1)-associ-
ated myocarditis (table 3).
The absence of consistent definitions for cardiotoxicity 
has implications for both clinical service delivery and 
research studies. In healthcare provision, there is a need 
for uniformity of coding for cancer and CVD across elec-
tronic health records and administrative data. Moreover, 
registries and audits tend to be disease group-specific. 
For example, in the UK, National Institute for Cardio-
vascular Outcomes Research audit do not hold detailed 
cancer data and the same is true for CVD recording in 
the Cancer Outcomes and Services Dataset registries. 
The prospect of data linkage across resources is therefore 
limited when studying across diseases and drugs. Defining 
cardiotoxicity consistently would advance consistency of 
diagnostic criteria, treatment thresholds, management 
and treatment targets. Instead, oncologists, in collabora-
tion with cardiologists, currently take decisions to start, 
temporarily suspend or permanently withhold cancer 
treatment on the basis of imprecise criteria for cardio-
toxicity and consensus rather than evidence and preci-
sion. This situation leads to suboptimal diagnosis and 
management, with unknown consequences on outcomes 
for these patients.
In research, the lack of interoperability of definitions 
of cardiotoxicity across trials, observational studies 
and registries stifles progress in discovery science (eg, 
genomic and –omic studies), translational science 
(new therapeutic targets) and clinical science (descrip-
tive epidemiology and trials). The universal definition 
of myocardial infarction illustrates how ontologies, 
including pathophysiology and clinical coding, can be 
aligned and simplified across academic and clinical prac-
tice.8 For cancer, survival is well-defined, thereby facili-
tating trials, systematic reviews and meta-analyses. ‘Big 
data’ (across resources, including cancer and CVD regis-
tries, routine electronic health records and biobanks 
with genomic information) and machine learning 
offer scope, traversing traditional silos to derive and 
use ‘evidence-based’ and ‘data-driven’ definitions for 
cardiotoxicity.
Cardio-oncology, as a specialty in its infancy, illustrates 
the progress but also the challenges facing precision 
medicine. The majority of obstacles to a unified definition 
of ‘cardiotoxicity’ are in the form of artificial boundaries 
across healthcare (disease-specific specialties and stages 
in patient pathways) and research disciplines (laboratory 
vs clinical vs data science). Precision medicine currently 
focuses within these boundary lines to identify thera-
peutic targets, but patients have always mandated a more 
holistic and dynamic approach. To advance the field of 
cardio-oncology, the central term ‘cardiotoxicity’ needs 
a definition which is structured, reliable and universally 
agreed by patients, health professionals and researchers. 
In order for precision medicine to move towards 4P medi-
cine (predictive, preventive, personalised and participa-
tory), collaborative approaches across cardiac specialties 
and cancer disciplines are necessary and facilitated in the 
‘big data’ era. Precision is not possible without precision 
of definition and diagnosis.
Table 3 Examples based on proposed universal definition of cardiotoxicity
Cardiotoxicity Timing Demographic Source Affected substrate
Doxorubicin Early Adult Anthracycline Cardiomyopathy
Late Paediatric Anthracycline Cardiomyopathy
Carfilzomib Acute Adult VEGF Hypertension
PD1/PDL1 Late Adult Immune Myocarditis
PD1, programmed cell death-1; PDL1, programmed death-ligand 1 VEGF, vascular endothelial growth factor.
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